Lung cancer remains the most prevalent malignancy and the leading cause of cancer-related mortality worldwide [1], with non-small cell lung cancer (NSCLC) being the predominant histological subtype. Surgical resection is the standard of care for patients with stage IB-IIA (T2N0M0) NSCLC. However, the role of adjuvant chemotherapy remains controversial as the balance between its survival benefits and associated side effects is still under evaluation.